News
Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020
Copenhagen, Denmark – Novo Holdings realised Total Income…
Futura Announces Collaboration with Menarini Korea to Commercialise MED3000 in South Korea
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a…
Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute
genex Bone Graft Substitute upgraded with a new closed-mixing…
Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals
Precirix NV, a clinical-stage biotechnology company developing…
Leucid Bio Chief Scientific Officer John Maher publishes new research on pCAR technology
New data highlight the strength and versatility of Leucid’s…
Neuraxpharm appoints Tom Coogan as new Country Manager for Ireland
Europe’s leading central nervous system specialty company…
BioInnovation Institute announces latest cohort of companies entering Venture Lab program
BioInnovation Institute (BII), an international commercial non-profit…
Novo Nordisk Foundation, Open Philanthropy, and Bill & Melinda Gates Foundation Launch Initiative to Support New Antiviral Medicines for Future Pandemics
COPENHAGEN – SAN FRANCISCO – SEATTLE. Today, the Novo Nordisk…
Biocomposites to present data on STIMULAN® at American Academy of Orthopaedic Surgeons Annual Meeting
Combination antibiotics released from STIMULAN completely kill…
Gadeta announces significant progress in advancing pipeline and TEG platform development
Aim is to develop gamma delta (γδ) T-cell receptor (TCR)-based…
James Brady Joins Verona Pharma as Non-Executive Director
LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) --…
Versameb CEO Klaas Zuideveld to Present at the RNA Leaders World Congress
Presentation demonstrates lead therapeutic candidate VMB-100…
Exact Therapeutics Announces Clinical Trial Update
OSLO/LONDON, 08 March 2022: EXACT THERAPEUTICS AS (“EXACT-Tx”,…
Destiny Pharma Fundraising to raise up to £7.0 million
Destiny Pharma plc (AIM: DEST) (the “Company” or “Destiny…
Neuraxpharm expands its business in Southeast Europe
Acquisition of Brain Therapeutics with operations in Greece, Cyprus…
Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Phase 3 ENHANCE program on track to report top-line COPD data…
Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie
March 1, 2022
Deal value of US$ 1 billion with…
Touchlight and Versameb announce GMP manufacturing supply agreement
Versameb moves forward with its lead asset towards clinical…
ISA Pharmaceuticals long term study confirms efficacy of our T-cell activating immunotherapy in combination with checkpoint inhibitor
Data published in the Journal of ImmunoTherapy of Cancer confirms…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
